Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study uses weekly surveys to monitor cancer Patients' symptoms remotely

NCT ID NCT05974150

Knowledge-focused Sponsor: Carevive Systems, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is gathering information from 25 adults with breast, lung, ovarian, multiple myeloma, or acute myeloid leukemia who are on active treatment. Participants fill out a short online survey each week for at least 12 weeks to report how they are feeling. The goal is to build a real-world dataset that could help improve symptom monitoring and care for future patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand and manage symptoms in real time for people with these cancers.
What could go wrong
This is a small, early-stage registry study (25 participants) that only collects data—it does not test a new treatment or directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients receiving cancer treatment for breast, lung, GI or multiple myeloma

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All participants must be 18 years of age or older. * Subjects may be any stage and anywhere in the treatment continuum. * Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma. * Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer. * All participants must be able to understand English. Exclusion Criteria: * Any patient who cannot understand written or spoken English. * Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer. * Any patient on a treatment clinical trial. * Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myelogenous leukemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia breast cancer breast neoplasm lung cancer lung neoplasm ovarian cancer plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myelogenous leukemia Breast cancer Lung cancer Multiple myeloma Ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cleveland Clinic Mercy Hospital

    RECRUITING

    Canton, Ohio, 44708, United States

  • Duke

    COMPLETED

    Durham, North Carolina, 27707, United States

  • Northshore University Health System

    RECRUITING

    Evanston, Illinois, 31024, United States

  • Tri-County Hematology & Oncology Associates, Inc.

    RECRUITING

    Massillon, Ohio, 44646, United States

  • Univeristy of North Carolina at Chapel Hill

    COMPLETED

    Chapel Hill, North Carolina, 27599, United States

  • University Hospitals Seidman Cancer Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • Yale Cancer Center

    COMPLETED

    New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.